2024-03-13T22:30:35.562Z

AK105-304

AK105-304
Nasopharynx cancer

A Randomized, Double blind, Multi center Phase III Study of Penpulimab (AK105) Combined with Chemotherapy versus Placebo Combined with Chemotherapy as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

A Randomized, Double blind, Multi center Phase III Study of Penpulimab (AK105) Combined with Chemotherapy versus Placebo Combined with Chemotherapy as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Trial overview

Topic

Nasopharynx cancer

Trial registration

Number: NCT04974398

Study details

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Further information

Click here for further information

Location

GenesisCare North Shore – PI: Dr Adrian Lee

 

GenesisCare North Shore – PI: Dr Adrian Lee   :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.